Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2012 2
2013 1
2015 2
2016 3
2017 1
2018 5
2019 7
2020 15
2021 27
2022 26
2023 31
2024 39
2025 46
2026 35

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

215 results

Results by year

Filters applied: . Clear all
Page 1
Setmelanotide.
[No authors listed] [No authors listed] 2024 Jul 5. LiverTox®: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2024 Jul 5. LiverTox®: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 39083631 Free Books & Documents. Review.
Setmelanotide is a melanocortin 4 receptor agonist that is used for chronic weight management for adults and children with rare genetic forms obesity due to gene defects in the melanocortin pathway. Setmelanotide therapy has not been associated serum aminotransferas …
Setmelanotide is a melanocortin 4 receptor agonist that is used for chronic weight management for adults and children with rare genet …
Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alstrom syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period.
Haqq AM, Chung WK, Dollfus H, Haws RM, Martos-Moreno GÁ, Poitou C, Yanovski JA, Mittleman RS, Yuan G, Forsythe E, Clément K, Argente J. Haqq AM, et al. Lancet Diabetes Endocrinol. 2022 Dec;10(12):859-868. doi: 10.1016/S2213-8587(22)00277-7. Epub 2022 Nov 7. Lancet Diabetes Endocrinol. 2022. PMID: 36356613 Free PMC article. Clinical Trial.
Patients were randomly assigned (1:1) using a numerical randomisation code to receive up to 3.0 mg of subcutaneous setmelanotide or placebo once per day during the 14-week double-blind period, followed by open-label setmelanotide for 52 weeks. ...Two patients had fo …
Patients were randomly assigned (1:1) using a numerical randomisation code to receive up to 3.0 mg of subcutaneous setmelanotide or p …
Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial.
Roth CL, Scimia C, Shoemaker AH, Gottschalk M, Miller J, Yuan G, Malhotra S, Abuzzahab MJ. Roth CL, et al. Lancet Diabetes Endocrinol. 2024 Jun;12(6):380-389. doi: 10.1016/S2213-8587(24)00087-1. Epub 2024 Apr 30. Lancet Diabetes Endocrinol. 2024. PMID: 38697184 Clinical Trial.
We investigated the melanocortin-4 receptor agonist setmelanotide for treatment of hypothalamic obesity. METHODS: This phase 2, open-label, multicentre trial was done in five centres in the USA. ...INTERPRETATION: These findings support setmelanotide as a novel effe …
We investigated the melanocortin-4 receptor agonist setmelanotide for treatment of hypothalamic obesity. METHODS: This phase 2, open- …
Setmelanotide: First Approval.
Markham A. Markham A. Drugs. 2021 Feb;81(3):397-403. doi: 10.1007/s40265-021-01470-9. Drugs. 2021. PMID: 33638809 Review.
Setmelanotide (IMCIVREE , Rhythm Pharmaceuticals) is a melanocortin-4 (MC4) receptor agonist developed for the treatment of obesity arising from proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency. ...This …
Setmelanotide (IMCIVREE , Rhythm Pharmaceuticals) is a melanocortin-4 (MC4) receptor agonist developed for the treatment of obesity a …
Setmelanotide: A Novel Targeted Treatment for Monogenic Obesity.
Pressley H, Cornelio CK, Adams EN. Pressley H, et al. J Pharm Technol. 2022 Dec;38(6):368-373. doi: 10.1177/87551225221116010. Epub 2022 Aug 30. J Pharm Technol. 2022. PMID: 36311304 Free PMC article. Review.
Data Sources: A literature review was performed by searching MEDLINE, SCOPUS, and EMBASE for all relevant English-language articles published between January 1, 1996, and November 30, 2021, using search terms obesity, setmelanotide, Imcivree, and MC4R agonist. Study Select …
Data Sources: A literature review was performed by searching MEDLINE, SCOPUS, and EMBASE for all relevant English-language articles publishe …
Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency.
Collet TH, Dubern B, Mokrosinski J, Connors H, Keogh JM, Mendes de Oliveira E, Henning E, Poitou-Bernert C, Oppert JM, Tounian P, Marchelli F, Alili R, Le Beyec J, Pépin D, Lacorte JM, Gottesdiener A, Bounds R, Sharma S, Folster C, Henderson B, O'Rahilly S, Stoner E, Gottesdiener K, Panaro BL, Cone RD, Clément K, Farooqi IS, Van der Ploeg LHT. Collet TH, et al. Mol Metab. 2017 Oct;6(10):1321-1329. doi: 10.1016/j.molmet.2017.06.015. Epub 2017 Jul 8. Mol Metab. 2017. PMID: 29031731 Free PMC article. Clinical Trial.
We sought to assess the efficacy of Setmelanotide in human MC4R deficiency. METHODS: We studied the effects of Setmelanotide on mutant MC4Rs in cells and the weight loss response to Setmelanotide administration in rodent studies and a human clinical trial. .. …
We sought to assess the efficacy of Setmelanotide in human MC4R deficiency. METHODS: We studied the effects of Setmelanotide o …
Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.
Clément K, van den Akker E, Argente J, Bahm A, Chung WK, Connors H, De Waele K, Farooqi IS, Gonneau-Lejeune J, Gordon G, Kohlsdorf K, Poitou C, Puder L, Swain J, Stewart M, Yuan G, Wabitsch M, Kühnen P; Setmelanotide POMC and LEPR Phase 3 Trial Investigators. Clément K, et al. Lancet Diabetes Endocrinol. 2020 Dec;8(12):960-970. doi: 10.1016/S2213-8587(20)30364-8. Epub 2020 Oct 30. Lancet Diabetes Endocrinol. 2020. PMID: 33137293 Clinical Trial.
Participants aged 6 years or older with POMC or LEPR deficiency obesity received open-label setmelanotide for 12 weeks. Participants with at least 5 kg weight loss (or 5% if weighing <100 kg at baseline) entered an 8-week placebo-controlled withdrawal sequence (includi …
Participants aged 6 years or older with POMC or LEPR deficiency obesity received open-label setmelanotide for 12 weeks. Participants …
Setmelanotide: A Melanocortin-4 Receptor Agonist for the Treatment of Severe Obesity Due to Hypothalamic Dysfunction.
Qamar S, Mallik R, Makaronidis J. Qamar S, et al. touchREV Endocrinol. 2024 Oct;20(2):62-71. doi: 10.17925/EE.2024.20.2.9. Epub 2024 Feb 9. touchREV Endocrinol. 2024. PMID: 39526054 Free PMC article. Review.
The emergence of a new therapeutic treatment, the melanocortin-4 receptor agonist setmelanotide (originally RM-493), has represented a breakthrough in the management of monogenic obesity and has raised hope in managing complex obesity. ...It also explores setmelanotide …
The emergence of a new therapeutic treatment, the melanocortin-4 receptor agonist setmelanotide (originally RM-493), has represented …
Setmelanotide: a promising advancement for pediatric patients with rare forms of genetic obesity.
Trapp CM, Censani M. Trapp CM, et al. Curr Opin Endocrinol Diabetes Obes. 2023 Apr 1;30(2):136-140. doi: 10.1097/MED.0000000000000798. Epub 2023 Feb 1. Curr Opin Endocrinol Diabetes Obes. 2023. PMID: 36722447 Free PMC article. Review.
PURPOSE OF REVIEW: Examine Setmelanotide use in patients with rare genetic variants that disrupt the melanocortin pathway. ...As a result, Setmelanotide was approved by the U.S. FDA in 2020 for chronic weight management in adult and pediatric patients 6 years of ag …
PURPOSE OF REVIEW: Examine Setmelanotide use in patients with rare genetic variants that disrupt the melanocortin pathway. ...As a re …
Setmelanotide for treating obesity caused by LEPR or POMC deficiency.
[No authors listed] [No authors listed] London: National Institute for Health and Care Excellence (NICE); 2022 Jul 6. London: National Institute for Health and Care Excellence (NICE); 2022 Jul 6. PMID: 40440436 Free Books & Documents. Review. No abstract available.
215 results